Innovación tecnológica frente a la expiración de patentes farmacéuticas: el nacimiento de las terapias digitales

  1. Marina Morla González 1
  1. 1 Universidad de León
    info

    Universidad de León

    León, España

    ROR https://ror.org/02tzt0b78

Revista:
Revista de derecho y genoma humano: genética, biotecnología y medicina avanzada

ISSN: 1134-7198

Año de publicación: 2023

Número: 59

Páginas: 55-88

Tipo: Artículo

DOI: 10.14679/3193 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Revista de derecho y genoma humano: genética, biotecnología y medicina avanzada

Resumen

La expiración de patentes farmacéuticas sobre medicamentos favorece la realización de prácticas comerciales dentro del sector que obstaculizan la entrada de los medicamentos genéricos. La creación de terapias digitales a través de la incorporación de componentes digitales en productos farmacéuticos tradicionales es una alternativa innovadora que combina la aportación de un valor añadido a un producto farmacéutico obsoleto a la vez que aborda problemas sanitarios serios de forma transformadora. Este tipo de prácticas podría ayudar a las empresas farmacéuticas a mantener su hueco de mercado tras la expiración de la patente de un medicamento superventas.

Referencias bibliográficas

  • AGRAWAL, M. Y THAKKAR, N., “Surviving patent expiration: strategies for marketing pharmaceutical products”, Journal of Product & Brand Management, Vol. 6, Núm. 5, 1997, pp. 305-314.
  • AIDS, “HIV prevention research advances unveiled at AIDS 2018”, Official Press Releasses, disponible en: http://www.aids2018.org/Media-Centre/The-latest/ Press-releases/ArticleID/184/HIV-prevention-research-advances-unveiled-atAIDS-2018
  • ASHBURN, T. T., THOR, K. B., “Drug Repositioning: Identifying and Developing New Uses for Existing Drugs”, Nature Reviews Drug Discovery, Vol. 3, Núm. 8. 2004, pp. 673-683.
  • AU-YEUNG, K. Y., Y DICARLO, L., “Cost comparison of wirelessly vs. directly observed therapy for adherence confirmation in anti-tuberculosis treatment”, The International Journal of Tuberculosis and Lung Disease, Vol. 16, Núm. 11, 2012, pp. 1498-1504.
  • BARTON, J., ET AL., Integrando los derechos de propiedad intelectual y la política de desarrollo Comisión sobre Derechos de Propiedad Intelectual, Comisión sobre Derechos de Propiedad Intelectual, Reino Unido, 2002.
  • BEALL, R. F. ET AL. New Drug Formulations and Their Respective Generic Entry Dates, Journal of Managed Care & Specialty Pharmacy, Vol. 25, Núm. 2, 2019, pp. 218-224.
  • BELKNAP, R. ET AL., “Feasibility of an Ingestible Sensor-Based System for Monitoring Adherence to Tuberculosis Therapy”, PLoS ONE, Vol. 8, Núm. 1, 2013, pp. 1-5.
  • BHAT, V. N., “Patent Term Extension Strategies in the Pharmaceutical Industry”, Pharmaceuticals Policy and Law, Vol. 6, 2005, pp. 109-22.
  • BLOOMBERG LAW, Otsuka Loses Abilify Patent Appeal, Court Affirms Zydus Win, disponible en: https://news.bloomberglaw.com/pharma-and-life-sciences/ otsuka-loses-abilify-patent-appeal-court-affirms-zydus-win.
  • BONACINI, M. ET AL., “Wirelessly Observed Therapy to Optimize Adherence and Target Interventions for Oral Hepatitis C Treatment: An Observational, Pilot Study”, Journal of Medical Internet Research, Vol. 22, Núm. 4, 2020, pp. 1-26.
  • BROWNE S. H., ET AL., “Wirelessly Observed Therapy (WOT): A New Paradigm in TB Therapy Monitoring. Abstract Body”, Conference on Retroviruses and Opportunistic Infections, disponible en: http://www.croiconference. org/sessions/wirelessly-observed-therapy-wot-new-paradigm-tb-therapymonitoring.
  • BROWNE, S. H. ET AL., “Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial”, PLoS Medicine, Vol. 16, Núm. 10, 2019, pp. 1-19
  • BROWNE, S.H., “Let Visuals Tell the Story: Medication Adherence in Patients with Type II Diabetes Captured by a Novel Ingestion Sensor Platform”, JMIR mHealth uHealth, Vol. 3, Núm. 4, 2015, pp. 1-19.
  • BULOW, J., “The Gaming of Pharmaceutical Patents”, SSRN Electronic Journal, Vol. 4, Núm. 1804, 2005.
  • BURDON, M. Y SLOPER, K., “The Art of Using Secondary Patents to Improve Protection”, Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, Vol. 3, Núm. 3, 2003, pp. 226-238.
  • BUSINESSWIRE, Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient Outcome
  • CHEN, J., “Adherence to PrEP, the HIV prevention drug, is low. A new study suggests a pill with a tiny sensor might help”, STAT
  • CHING, A. T., “Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration”, International Journal of Industrial Organization, Vol. 28, Núm. 6, 2010, pp. 619-638.
  • DE MIGUEL BERIAIN, I. Y MORLA GONZÁLEZ, M., “‘Digital Pills’ for Mental Diseases: An Ethical and Social Analysis of the Issues behind the Concept”, Journal of Law and the Biosciences, Vol. 7, Núm. 1, 2020, pp. 1-19.
  • DICARLO, L. ET AL., “PCV16 Real-Time assessment of medication taking and activities of daily living in patients with uncontrolled hypertension”, Value in Health, Vol. 17, 2014, A323-A686.
  • DRUGS.COM (Febrero, 2014), U. S. Pharmaceutical Sales-2013.
  • DUBEY, R., Y DUBEY J., “Pharmaceutical Product Differentiation: A Strategy for Strengthening Product Pipeline and Life Cycle Management”, Journal of Medical Marketing, Vol. 9, Núm. 2, 2009, pp. 104-118.
  • EISENBERGER, U. ET AL., “Medication Adherence Assessment: High Accuracy of the New Ingestible Sensor System in Kidney Transplants”, Transplantation, Vol. 96, Núm. 3, 2013, pp. 245-250.
  • ESPLUGUES MOTA, C., “Comercio internacional de medicamentos: Algunas cuestiones relevantes”, Retos de la investigación y comercialización de nuevos fármacos, Cátedra Interuniversitaria Fundación BBVA-Diputación Foral de Bizkaia de Derecho y Genoma Humano, Comares, Bilbao-Granada, 2009, pp. 77-103.
  • FRIAS, J. ET AL., “Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial”, Journal of Medical Internet Research, Vol. 19, Núm. 7, 2017, p. 1-17.
  • GODBEHERE, P. Y WAREING, P., “Hypertension Assessment and Management: Role for Digital Medicine”, The Journal of Clinical Hypertension, Vol. 18, Núm. 3, 2014.
  • GÓMEZ SÁNCHEZ, Y., “La libertad de creación y producción científica: especial referencia a la ley de investigación biomédica”, Uned. Revista de Derecho Político, Vol. 75-76, 2009, pp. 489-514.
  • GRABOWSKI, H. Y VERNON, J. M., “Effective Patent Life in Pharmaceuticals”, Int. J. Technology Management, Vol. 17, Núm. 1/2, 2000, pp. 98-120.
  • GRABOWSKI, H., Y MOE, J. L., “Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention”, Cancer Prevention Research, Vol. 1, Núm. 2, 2008, pp. 84-90.
  • HAFEZI, H. ET AL., An Ingestible Sensor for Measuring Medication Adherence, IEEE Transactions on Biomedical Engineering, 62(1), 2015, pp 99-109.
  • HAFFNER, M. E., ET AL, “Does Orphan Drug Legislation Really Answer the Needs of Patients?”, The Lancet, Vol. 371, Núm. 9629, 2008, pp. 2041-2044.
  • HITCHCOCK, J., Y TUGAL, B, “The latest thinking on best strategies for use of supplementary certificates”, Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, Vol. 3, Núm. 3, 2003, pp. 220- 225.
  • HOLLIS, A., “The Importance of Being First: Evidence from Canadian Generic Pharmaceuticals”, Health Economics, Vol. 11, Núm. 8, 2002, pp. 723-734.
  • JAAM, M. ET AL., “A Qualitative Exploration of Barriers to Medication Adherence among Patients with Uncontrolled Diabetes in Qatar: Integrating Perspectives of Patients and Health Care Providers, Patient Preference and Adherence, Vol. 12, 2018, pp. 2205-2216.
  • JANSEN, M., “Protecting the big names in medicine”, The Quaterly Law Review for People Business, Vol. 11, Núm.4, 2003, pp. 212-215.
  • JIMÉNEZ, J., “El CEO de Novartis habla sobre crecer tras un precipicio de patentes”, Harvard Bussiness Review
  • KANE, J.M. ET AL., “First Experience With a Wireless System Incorporating Physiologic Assessments and Direct Confirmation of Digital Tablet Ingestions in Ambulatory Patients With Schizophrenia or Bipolar Disorder”, The Journal of Clinical Psychiatry, Vol. 74, Núm. 6, 2013, pp. 533-540.
  • KIM, Y.A., “PMD14 An economic model of the impact of digital medicines with a Mobile application in patients with Comorbid Hypertension, Diabetes, and Hypercholesterolemia”, Value in health, 18, 2015, A1-A307.
  • KVESIC, D. Z., “Product Lifecycle Management: Marketing Strategies for the Pharmaceutical Industry”, Journal of Medical Marketing, Vol. 8, Núm. 4, 2008, pp. 293-301.
  • KVESIC, D. Z., “Product Lifecycle Management: Marketing Strategies for the Pharmaceutical Industry”, Journal of Medical Marketing, Vol. 8, Núm. 4, 2008, pp. 293-301.
  • MANSFIELD, E., “Patents and Inventors: An Empirical Study”, Management Science, Núm. 32, Vol. 2, pp. 173-181.
  • MARTÍNEZ VELENCOSO, L. M., La protección jurídica de la persona en el ámbito de la Biotecnología y del Big Data, Dykinson: Madrid, 2021.
  • MONROE, J. B., Otsuka Prevails in U.S Abilify Patent Appeal, Finnegan
  • MOORHEAD, P. ET AL., “Efficacy and safety of a medication dose reminder feature in a digital health offering with the use of sensor-enabled medicines”, Journal of the American Pharmacists Association, Vol. 30, 2017, pp. 1-7.
  • MORLA GONZÁLEZ, M., Medicina personalizada de precisión y derechos fundamentales, Tirant LoBlanch: Madrid, 2023.
  • NAIK, R. ET AL., “First Use of an Ingestible Sensor to Manage Uncontrolled Blood Pressure in Primary Practice: The UK Hypertension Registry”, Journal of Community Medicine & Health Education, Vol. 7, Núm. 1, 2017, pp. 1-5.
  • NOBLE, K., ET AL., “Medication adherence and activity patterns underlying uncontrolled hypertension: Assessment and recommendations by practicing pharmacists using digital health care”, Journal of the American Pharmacists Association, Vol. 56, 2016, pp. 310-315.
  • OSTERBERG, L. ET AL., “First clinical evaluation of a digital health offering to optimize treatment in patients with uncontrolled hypertension and type 2 diabetes”, Journal of the American College of Cardiology, Vol. 67, Núm.13, 2019.
  • PAINE, C. S., “Brand-Name Drug Manufacturers Risk Antitrust Violations By Slowing Generic Production Through Patent Layering”, Shelton Hall Law Review, Vol. 33, Núm. 2, 2003, pp. 479. 503.
  • ROVIRA, J., “Innovación y acceso a los medicamentos: ¿necesitamos un compromiso entre objetivos o un cambio de paradigma?”, Salud pública y patentes farmacéuticas. Cuestiones de Economía, política y derecho, Seuba, Xavier (coord.). pp. 43-70.
  • SACHS, J. “The Global Innovation Divide”, Innovation Policy and the Economy, 3, 2003 pp. 131-141.
  • SCOOTER PLOWMAN, R. ET AL., “Digital medicines: clinical review on the safety of tablets with sensors”, Expert Opinion on Drug Safety, Vol. 17, Núm. 9, 2018, pp. 849-852.
  • SEUBA, X., La protección de la salud ante la regulación internacional de los productos farmacéuticos, Marcial Pons, Madrid, 2010.
  • SONG, C. H ET AL., “Product-Line Extensions and Pricing Strategies of Brand-Name Drugs Facing Patent Expiration” J. Manag. Care Pharm, vol. 11, 2014, pp. 746-775.
  • SONG, C. H., Y HAN J. W., “Patent Cliff and Strategic Switch: Exploring Strategic Design Possibilities in the Pharmaceutical Industry”, SpringerPlus, Vol. 5, Núm. 1, 2016, pp. 1-14.
  • SULKOWSKI, M.S. ET AL., “1554 Efficacy and adherence to oral Hepatitis C (hcv) treatment through a digital medicine program (dmp) among a population at high risk for nonadherence” (Conference paper, 12 de noviembre de 2019)
  • SULLIVAN, S. ET AL., “Impact of a Novel Digital Medicine Program on Adherence and Utilization in Pediatric Transplant Patients”, 2019 American Transplant Congress
  • SUSMAN, E., “Tech-Driven Adherence Monitoring Comes to HIV -Embedded sensor tells whether patients take their meds”, MedPageToday.
  • TRIPLETT, K.N. ET AL., “Digital medicine program with pediatric solid organ transplant patients: Perceived benefits and challenges”, Pediatric Transplantation, Vol. 23, Núm. 7, 2019, pp. 1-12.
  • VIRDI, N. ET AL., “P134 Optimizing treatment in patients with uncontrolled hypertension and type 2 diabetes by using a digital health offering”, Journal of the American Society of Hypertension, Vol. 10, Núm. 4s, 2016, e56-e73.
Fuente de los datos: Dialnet